Download Free Sample
Author
Muni Kumar Meravath is a seasoned Healthcare Market Research Analyst with over 6 years of experience in the healthc.....
PARP Inhibitors Market: Competitive Landscape, Pipeline, and Market Analysis 2023
PARP Inhibitors Market: Competitive Landscape, Pipeline, and Market Analysis 2023
PARP stands for poly-ADP-ribose polymerase and is an enzyme found in the cells which helps the cells repair their DNA whenever it is damaged. The PARP family has many essential functions in cellular processes, including the DNA damage response, apoptosis, and regulation of transcription. PARP1 and PARP2 are the two types of PARPS that are involved in DNA repair. The mechanism of action is first, PARP1 binds to sites of single-strand DNA damage via the DNA-binding domain. Further, it synthesizes the PAR part and transfers it to the acceptor protein, and PAR recruits other repair proteins to the damaged DNA site. PARP Inhibitors inhibit the enzyme PARP from doing DNA repair and thus leave the cell to proceed through the apoptosis process. These are beneficial in the treatment of various cancers like Ovarian cancer, Breast cancer, Prostate cancer, and others, wherein they block the DNA repair of cancer cells, causing their death. Companies are trying to find new and novel molecules to prevent and cure these diseases. The development and launch of newer products by the market players will significantly enhance the revenue of the PARP Inhibitors market over the forecast years. For instance, according to the World Cancer Research Fund International, in 2020, ovarian cancer was the 8TH most common cancer in women globally, with more than 313,000 new cases. Also, according to the American Cancer Society, in 2023, it is estimated that about 19,710 women will receive a new diagnosis of ovarian cancer.
Several of these inhibitors are on the market, while many are in ongoing clinical trials. Companies in their pipelines have 112 products in various stages of clinical trials. 2 products are in Phase 4, 7 products are in Phase 3, 16 products are in Phase 2, and 7 products are in Phase 1 of the clinical trials.
Key Developments of PARP Inhibitors
Approved molecules
Drugs in Pipeline
Clinical Activity and Developments of PARP Inhibitors
As of June 2023, 112 products for 438 diseases are in clinical trials. For instance,
|
Molecule name |
Number of studies |
|
Lynparza (Olaparib) |
372 |
|
Zejula (Nilaparib) |
174 |
|
Rubraca (Rucaparib) |
60 |
|
AiRioYui (Fluzoparib) |
60 |
|
Talzenna (Talazoparib) |
8 |
Drugs like Lynparza (Olaparib) and Talzenna (talazoparib) are approved by the USFDA and European EU for use, i.e., patients for use the treatment of BRCA-mutated Metastatic Castration-Resistant Prostate Cancer (mCRPC) and homologous recombination repair (HRR) gene-mutated Metastatic Castration-Resistant Prostate Cancer (mCRPC) respectively. Cancer cells are killed by PARP inhibitors in a variety of ways other than just by preventing PARP from doing its job. The trapping action of PARP inhibitors on PARP is the oldest mechanism. In addition to altering the function of PARP proteins after attaching to the NAD binding site of PARP, PARP inhibitors also glue PARP proteins to damaged DNA without causing them to dissociate, which leads to the buildup of the PARP-DNA nuclear protein complex and the amplification of replication forks. In the end, not only can SSB not be repaired, but RF stalling also causes the extremely cytotoxic DSBs to degrade. Other indications for which PARP Inhibitors are used include Primary peritoneum cancer, Breast cancer, Pancreatic cancer, and Fallopian tube cancer. These are used as the 1st line, 2nd line, and also as the 3rd line of therapy either solely or in combination with other drugs to improve outcomes. There is a great opportunity for the companies to launch their new products and innovations in the market.
The global net sales of Lynparza by AstraZeneca were $2.6 billion in the financial year 2022, which was 12% more than the sales in 2021, and Merck and Co. generated a revenue of $1116 million in the financial year 2022, which was 13% more than the last year. In the USA, Lynparza generated a sales revenue of $1,226 million in the financial year 2022. The global net sales of Zejula (niraparib) were $578.19 million in the financial year 2022. The sales of the drugs are driven by an increasing prevalence of indicated diseases. USA and Europe’s favorable reimbursement policies make the drugs available to their people at an affordable price. Along with this, good insurance coverage is given by the government, that act as the growth driver for the market.
Latin America
Europe
Asia Pacific
Middle East
North America
Download Free Sample Report
Lynparza (olaparib), Zejula (niraparib), and Talzenna (Talazoparib) are approved by the FDA, while Rubraca (rucaparib) has received accelerated approval from the FDA.
These are being used in various indications like Ovarian cancer, Prostate cancer, Breast cancer, and others.
Merck (MSD), AstraZeneca, GSK plc., J&J, and Pfizer are some of the major market players for PARP Inhibitors.
Rising incidence of diseases, improvement in technologies, development of new treatment lines in the market, and changing lifestyles leading to different types of cancers like Breast cancer, Prostate cancer, and Fallopian tube cancer are the key opportunities for PARP Inhibitors in the market.
Key Market Players
Author
Muni Kumar Meravath is a seasoned Healthcare Market Research Analyst with over 6 years of experience in the healthcare domain, encompassing pharmaceuticals, medical devices, and diagnostics. A graduate in Pharmacy, he possesses a strong foundation in the intricacies of the healthcare sector. He further enhanced his expertise by pursuing an MBA in Pharmaceuticals, equipping him with valuable business acumen. His analytical skills and market insights have contributed to strategic decision-making and enhanced market positioning for various healthcare organizations. Committed to driving innovation and excellence, Muni continues to seek opportunities to improve healthcare delivery through data-driven insights.